Insmed Beheer

Beheer criteriumcontroles 2/4

De CEO Insmed is Will Lewis, benoemd in Sep2012, heeft een ambtstermijn van 11.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.79M, bestaande uit 9.4% salaris en 90.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.29% van de aandelen van het bedrijf, ter waarde MX$ 184.59M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 9.8 jaar.

Belangrijke informatie

Will Lewis

Algemeen directeur

US$7.8m

Totale compensatie

Percentage CEO-salaris	9.4%
Dienstverband CEO	11.5yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	9.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Will Lewis's beloning veranderd ten opzichte van Insmed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	-US$750m
Sep 30 2023	n/a	n/a	-US$724m
Jun 30 2023	n/a	n/a	-US$696m
Mar 31 2023	n/a	n/a	-US$547m
Dec 31 2022	US$8m	US$735k	-US$482m
Sep 30 2022	n/a	n/a	-US$434m
Jun 30 2022	n/a	n/a	-US$416m
Mar 31 2022	n/a	n/a	-US$438m
Dec 31 2021	US$7m	US$710k	-US$435m
Sep 30 2021	n/a	n/a	-US$424m
Jun 30 2021	n/a	n/a	-US$375m
Mar 31 2021	n/a	n/a	-US$319m
Dec 31 2020	US$6m	US$660k	-US$294m
Sep 30 2020	n/a	n/a	-US$245m
Jun 30 2020	n/a	n/a	-US$242m
Mar 31 2020	n/a	n/a	-US$247m
Dec 31 2019	US$7m	US$641k	-US$254m
Sep 30 2019	n/a	n/a	-US$293m
Jun 30 2019	n/a	n/a	-US$320m
Mar 31 2019	n/a	n/a	-US$330m
Dec 31 2018	US$6m	US$610k	-US$324m
Sep 30 2018	n/a	n/a	-US$298m
Jun 30 2018	n/a	n/a	-US$256m
Mar 31 2018	n/a	n/a	-US$224m
Dec 31 2017	US$4m	US$567k	-US$193m

Compensatie versus markt: De totale vergoeding ($USD 7.79M ) Will } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 1.31M ).

Compensatie versus inkomsten: De vergoeding van Will is gestegen terwijl het bedrijf verliesgevend is.

CEO

Will Lewis (54 yo)

11.5yrs

Tenure

US$7,789,898

Compensatie

Mr. William H. Lewis, also known as Will, J.D., M.B.A., serves as Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January, 2024. He has been Chief Executive Officer and President at...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Lewis	President	11.5yrs	US$7.79m	0.29% MX$ 184.6m
Sara Bonstein	Chief Financial Officer	4.2yrs	US$3.43m	0.0035% MX$ 2.2m
Roger Adsett	Chief Operating Officer	4.3yrs	US$4.64m	0.040% MX$ 25.4m
John Wise	Chief Commercial Officer	4.3yrs	US$4.02m	0.030% MX$ 18.9m
Martina Flammer	Chief Medical Officer	4.3yrs	US$3.76m	0.0041% MX$ 2.6m
Brian Kaspar	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Eleanor Barisser	Associate Director of Investor Relations	no data	geen gegevens	geen gegevens
Michael Smith	Chief Legal Officer & Corporate Secretary	2.7yrs	geen gegevens	0.058% MX$ 37.1m
Mandy Fahey	Executive Director of Corporate Communications	no data	geen gegevens	geen gegevens
S. Schaeffer	Chief People Strategy Officer	11.2yrs	US$2.66m	0.025% MX$ 15.8m
Eugene Sullivan	Chief Product Strategy Officer	6.8yrs	US$1.69m	geen gegevens
Neil Hughes	GM & Head of Europe	4.8yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van INSM * wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
William Lewis	President	11.5yrs	US$7.79m	0.29% MX$ 184.6m
David W. McGirr	Independent Director	10.4yrs	US$320.00k	0.049% MX$ 31.2m
Melvin Sharoky	Independent Director	22.8yrs	US$312.50k	0.22% MX$ 138.2m
Alfred Altomari	Independent Director	11.6yrs	US$312.70k	0.029% MX$ 18.5m
David Brennan	Lead Independent Director	9.8yrs	US$342.30k	0.064% MX$ 41.1m
Clarissa Desjardins	Independent Director	4.3yrs	US$315.00k	0.024% MX$ 15.3m
Elizabeth Anderson	Independent Director	5.3yrs	US$310.00k	0.029% MX$ 18.2m
Leo Lee	Independent Director	5.8yrs	US$315.00k	0.066% MX$ 42.2m
Carol Schafer	Independent Director	3.9yrs	US$315.00k	0.021% MX$ 13.7m

9.8yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INSM * wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.8 jaar).

Insmed Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insufficient new directors

Insufficient new directors

President recently sold Mex$2.7m worth of stock

Insufficient new directors

Independent Director recently bought Mex$16m worth of stock

Recent updates

Insmed Incorporated Reiterates earnings Guidance for the Year 2024

Insmed Incorporated to Report Q3, 2024 Results on Oct 31, 2024

Insmed Incorporated Presents New Subgroup Analyses from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Insufficient new directors

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Insufficient new directors

President recently sold Mex$2.7m worth of stock

Insufficient new directors

Independent Director recently bought Mex$16m worth of stock

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$1.09 loss per share (vs US$0.96 loss in 3Q 2021)

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Senior VP recently sold Mex$143k worth of stock

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$1.07 loss in 2Q 2021)

Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022

Insmed Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Senior VP & General Counsel recently sold Mex$457k worth of stock

Senior VP & General Counsel recently sold Mex$457k worth of stock

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd